Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Rau, C; Auer-Hackenberg, L; Deubzer, HE; Schwabel, E; Jaros, M; Diederichs, A; Lehrnbecher, T; Holm, M; von, Linstow, ML; Martin, L; Dinges, SS; Rothensteiner, M; Siepermann, M; Strenger, V; von, Both, U; Teig, N; Brinkmann, F; Leeb, F; Zeitlinger, M; Kobbe, R; Götzinger, F.
Treatment of Infants and Children With SARS-CoV-2 Monoclonal Antibodies: A European Case Series.
Pediatr Infect Dis J. 2023; 42(2): 125-129.
Doi: 10.1097/INF.0000000000003773
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Strenger Volker
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Although severe COVID-19 in children is rare, those with certain pre-existing health conditions are more prone to severe disease. Monoclonal antibodies (mAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are potent antiviral agents that reduce adverse clinical outcomes in adults, but are commonly not approved for use in pediatric patients. METHODS: We retrospectively evaluated mAb treatment in children <12 years of age or <40kg with SARS-CoV-2 infection between January 1, 2021, and March 7, 2022, in 12 tertiary care centers in 3 European countries. RESULTS: We received data from 53 patients from Austria, Denmark and Germany. Median age was 5.4 years [0-13.8, interquartile range (IQR) = 6.2], and median body weight was 20 kg (3-50.1, IQR = 13). The most frequent SARS-CoV-2 variant in this study, if known, was Omicron, followed by Delta and Alpha. Pre-existing conditions included immunodeficiency, malignancy, hematologic disease, cardiac disease, chronic lung disease, chronic liver disease, kidney disease and diabetes. Forty-two patients received sotrovimab (79%), 9 casirivimab/imdevimab (17%) and 2 bamlanivimab (4%). All but 1 patient survived. Median duration of hospital stay was 3 days (0-56, IQR = 6). Seven patients required treatment in an intensive care unit, and 5 required high-flow nasal cannula treatment. Potential side effects included neutropenia (6/53, 11%), lymphopenia (3/53, 6%), nausea or vomiting (2/53, 4%), rise of alanine transaminase (1/53, 2%) and hypotonia (1/53, 2%). CONCLUSIONS: MAb treatment was well tolerated by children in this cohort.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult - administration & dosage
- Humans - administration & dosage
- Child - administration & dosage
- Infant - administration & dosage
- Child, Preschool - administration & dosage
- COVID-19 - administration & dosage
- Retrospective Studies - administration & dosage
- SARS-CoV-2 - administration & dosage
- Leukopenia - administration & dosage
- Antibodies, Monoclonal - therapeutic use
- Antibodies, Neutralizing - administration & dosage
- Antibodies, Viral - administration & dosage
- Chronic Disease - administration & dosage
- Find related publications in this database (Keywords)
- SARS-CoV-2
- COVID-19
- children
- treatment
- monoclonal antibodies